<MedlineCitation Status="Completed">
<MedlineID>10011539</MedlineID>
<PMID>420899</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-3223</ISSN>
<JournalIssue>
<Volume>14</Volume>
<Issue>1</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Cognitive abnormality in schizophrenia: a dual-process model.</ArticleTitle>
<Pagination>
<MedlinePgn>155-76</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Kay</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
</Author>
<Author>
<LastName>Singh</LastName>
<ForeName>M M</ForeName>
<Initials>MM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Biol Psychiatry</MedlineTA>
<NlmUniqueID>0213264</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>50-53-3</RegistryNumber>
<NameOfSubstance>Chlorpromazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>52-86-8</RegistryNumber>
<NameOfSubstance>Haloperidol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adolescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Arousal</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Attention</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Chlorpromazine</DescriptorName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cognition Disorders</DescriptorName>
<QualifierName>drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Color Perception</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Concept Formation</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Drug Resistance</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Form Perception</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Haloperidol</DescriptorName>
<QualifierName>therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Models, Psychological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Psychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Schizophrenia</DescriptorName>
<QualifierName>drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Schizophrenia, Catatonic</DescriptorName>
<QualifierName>psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Schizophrenia, Disorganized</DescriptorName>
<QualifierName>psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Schizophrenia, Paranoid</DescriptorName>
<QualifierName>psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
